Veradermics, Inc (MANE) company profile
Close on Nov 13, 2026Market cap $5.42BP/E –Yield –
About Veradermics
Pharmaceutical Preparations, SIC 2834
The company is a clinical-stage biopharmaceutical business focused on developing therapeutic treatments for common aesthetic and dermatological conditions. Its core initiative centers on treating pattern hair loss in men and women, an underserved condition characterized by high treatment failure and low satisfaction. The lead product candidate is VDPHL01, an oral extended-release minoxidil formulation engineered to stimulate hair growth while minimizing off-target cardiac stimulative risks. The company’s prospective customer base consists of male and female patients suffering from pattern hair loss.
In terms of scale and geographic operations, the provided excerpt describes clinical activities focused on the United States, including registration-directed clinical trials designed to enroll over 1,600 male and female participants across multiple centers. The enterprise retains exclusive worldwide rights to its portfolio of product candidates. Specific operational facilities, physical office counts, and corporate headquarters locations are not stated in the text.
Summary of the business section of Veradermics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Veradermics, Inc
- Headquarters
- New Haven, CT
- Address
- 470 James Street 06513
- Phone
- (228) 372-3376
- Website
- veradermics.com
- Employees
- 21, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Hartford, Connecticut
Stock & identifiers
- Ticker
- MANE
- Exchange
- NYSE
- IPO date
- Feb 4, 2026
- Shares outstanding
- 42M, Aug 6, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1827635
- CUSIP
- 922967104
- ISIN
- US9229671048
- FIGI
- BBG00Z1S1G39
- Share class FIGI
- BBG00Z1S1G48
- EIN
- 84-3304423
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Reid Alexander Waldman | Chief Executive Officer, Director | 170,824 |
| David Hollander | Chief R&D Officer | 9,650 |
| Timothy August Durso | Chief Technical Officer | 195,020 |
| Michael V. Greco | General Counsel | – |
| Mark Neumann | Chief Commercial Officer | – |
| Dominic Gabriel Carrano | Chief Financial Officer | – |
| Patrick G. Enright | Director | 1,803,474 |
| Averill Madison Master Fund, Ltd. | Director | – |
| Averill Master Fund, Ltd. | Director | 3,106,937 |
| Montanova Capital, Llc | Director | 520,453 |
| John W. Childs | Director | 199,117 |
| David Matthew Friedman | Director | – |
| Vlad Coric | Director | 768,735 |
| Katarina Pance | Director | – |
| Jane M. Grant-Kels | Director | 2,455 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 4, 2026
- Offer price
- $17.00
- Securities offered
- 15,077,647
- Gross proceeds
- $256.32M
- Exchange
- NYSE
- First trading day
- Feb 4, 2026
- First-day close
- $37.75+122.1%
- Lock-up ends (est.)
- Aug 3, 2026
“The initial public offering price is $17.00 per share of our common stock.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 4, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 3, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?